by admin | Sep 22, 2021 | News
Listen now
by admin | Aug 27, 2021 | News
Antibody therapeutics revolutionised how diseases like cancer are treated in the developed world, but their high manufacturing cost and cumbersome distribution and administration leave them out of reach for most. In this guest article, Lumen Bioscience’s CEO, Brian...
by admin | Aug 11, 2021 | News
Today Lumen announced the first results of our long-running collaboration with Google’s world-beating AI/ML (machine learning) team. The gist: advanced algorithms helped us navigate a dizzying amount of data to double the productivity of cGMP biologics manufacturing...
by admin | Aug 10, 2021 | News
Listen now
by admin | Aug 8, 2021 | News
ABSTRACT Background Arthrospira platensis (commonly known as spirulina) is a promising new platform for low-cost manufacturing of biopharmaceuticals. However, full realization of the platform’s potential will depend on achieving both high growth rates of spirulina and...
by admin | Jun 16, 2021 | News
Today Lumen announced a new collaboration with Novo Nordisk to explore new treatments for cardiometabolic diseases. We couldn’t be more thrilled. Cardiometabolic disease — a cluster of related conditions that includes obesity, diabetes, and cardiovascular disease —...
Reviewing Real-World Safety and Efficacy Data on C difficile Therapy Rebyota
LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
Preventive antimicrobials: A promising solution to antibiotic resistance
Preventive Biologics May Aid the Antibiotic Resistance Crisis